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ABSTRACT 
In this case-controlled study, we tested susceptible genetic variants for Alzheimer’s disease 
(AD) in CR1, CLU and PICALM from Genome Wide Association studies (GWAS) in 
southern Chinese population. 812 participants consisting of 462 late-onset Alzheimer’s 
disease (LOAD) patients and 350 non-demented controls were recruited. We found by 
multivariate logistic regression analysis, that single nucleotide polymorphisms (SNPs) in CR1 
(rs6656401 adjusted allelic p=0.035, adjusted genotypic p=0.043) and CLU (rs2279590 
adjusted allelic p=0.035, adjusted genotypic p=0.006; rs11136000 adjusted allelic p=0.038, 
adjusted genotypic p=0.009) were significantly different between LOAD patients and 
non-demented controls. For PICALM, LOAD association was found only in the APOE ε4 (-) 
subgroup (rs3851179 adjusted allelic p=0.028, adjusted genotypic p=0.013). Our findings 
showed evidence of CR1, CLU and PICALM and LOAD susceptibility in an independent 
southern Chinese population, which provides additional evidence for LOAD association apart 
from prior GWAS in Caucasian population. 
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1. Introduction 
Alzheimer’s disease (AD), characterized with progressive cognitive impairments, is the most 
common form of dementia in an aging population. Although the underlying cause is uncertain, 
it is widely acknowledged that the involvement of heredity genetic risk factors in AD’s 
predisposition and progression (Goate, et al., 1991,Rogaev, et al.,1995,Sherrington, et 
al.,1995). At present, APOE which carries three alleles ε2, ε3, and ε4, is the unique and well 
established susceptibility gene for LOAD (Saunders, et al., 1993). The consistent result of 
association between APOE ε4 and an increased disease risk has been confirmed in different 
ethnic populations based on candidate-gene approaches as well as Genome Wide Association 
studies (GWAS) (Bertram and Tanzi, 2008). Moreover, researches showed the heterozygous 
APOE ε4 carriers have two-fold increased risk and the homozygous carriers have eleven-fold 
increased risk for LOAD development compared to APOE ε3 carriers in Caucasian population 
(Bickeboller, et al., 1997). However, with 65% sensitivity and 68% specificity, the impact of 
APOE ε4 allele for LOAD diagnosis is limited and can’t benefit clinics (Mayeux, et al., 1998). 
Thus, further study to identify novel LOAD genetic risk markers is warranted. 
 
To date, a number of genetic variants from different genes have been reported to be related 
with LOAD susceptibility by using new large scale genotyping technologies according to 
AlzGene database (http://www.alzforum.org/res/com/gen/alzgene/largescale.asp). However, 
none of those genes exhibited replicable results for disease risk association until recently CLU 
was simultaneously reported by two independent research groups both based on GWAS 
approach. In one GWAS performed by Lambert and his colleagues among subjects recruited 
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from France, Finland, Belgium, Spain and Italy, results showed evidence of SNPs in CLU, 
CR1 and LOAD association. Further analysis revealed the interaction between those loci and 
APOE ε4 status for disease risk (Lambert, et al., 2009). Findings from the other GWAS 
conducted by Harold et al on Europeans and Americans demonstrated a novel locus at 5’ in 
PICALM associated with LOAD in addition to the same susceptible variant in CLU. However, 
contrary to Lambert’s results, they didn’t detect the interaction between those polymorphisms 
with APOE ε4 status on LOAD risk (Harold, et al., 2009). 
 
The overlap, as well as the contradiction of these two GWAS’ results promoted the present 
replication genetic study focusing on the Chinese population. Currently, the prevalence of AD 
in China is 1.6% in elderly (>60 years) which is imposing a tremendous economic burden to 
family and society (Dong, et al., 2007,Song and Wang, 2010). To better understand the 
genetic aspect of LOAD in Chinese ethnic population, we therefore followed those 
susceptible polymorphisms of CLU, CR1 and PICALM from GWAS in an independent 
Chinese sample set.  
 
2. Methods 
2.1 Subjects 
Subjects of this case-controlled study were recruited from the Memory Clinic of Queen Mary 
Hospital and community elderly social centers in Hong Kong. This is an on-going aging and 
dementia project in the University of Hong Kong, which has been reported previously (Li, et 
al., 2006,Li, et al., 2009,Li, et al., 2010). The Institutional Review Board (IRB) of the 
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University of Hong Kong and the Hospital Authority Hong Kong West Cluster (HKU/HA 
HKW IRB) approved this study. Written consents were obtained from all participants. In 
addition to detailed physical and neurological examinations, all participants were subjected to 
laboratory investigations: thyroid function test; serum vitamins B12 and folate levels tests; 
and red blood cell (RBC) folate level test. CT brain scans were done for patients with LOAD 
but not for the non-demented controls. All subjects were rated by a single rater (L.W.C) with 
the Clinical Dementia Rating Scale (CDR) (Hughes, et al., 1982). Cognitively normal 
controls were given CDR rating of 0. For LOAD patients, the CDR ranged from 0.5 to 3.0, 
depending on the severity of the dementia. The probable LOAD was diagnosed according to 
the criteria of the National Institute of Neurological and Communicative Disorders and 
Stroke – Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA criteria) 
(McKhann, et al., 1984). We excluded subjects with secondary causes of dementia, non-AD 
types of dementia and familial AD.  
 
2.2 DNA extraction  
Genomic DNA was isolated from the whole blood by using QIAamp DNA Blood Mini Kit 
(Qiagen, Germany) in accordance with protocol. The quality and quantity of DNA were 
evaluated on a fluorometer.  
 
2.3 Genotyping 
Seven previously published GWAS SNPs (rs3818361 and rs6656401 of CR1; rs11136000, 
rs2279590 and rs9331888 of CLU; rs3851179 and rs541458 of PICALM) were selected for 
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genotyping. Both amplification and single allele extension primers were designed by Mass 
ARRARY AssayDesign software. Subsequent genotyping for those selected polymorphisms 
were investigated on Sequenom
®
 San Diego, CA
 
platform following the manufacturer’s 
protocols. APOE genotyping was done by the restriction fragment length polymorphism 
(RFLP) approach according to a modified method (Song, et al.,1998).  
 
2.4 Statistical analysis 
Data analysis was performed by PLINK (http://pngu.mgh.harvard.edu/~purcell/plink). The 
differences of allele frequencies and genotype distributions between groups were calculated 
by X
2
 test. Multivariate logistic regression model was used to obtain adjusted association 
p-values (adjusted for age, sex and APOE ε4 status) to exclude the potential effects of 
confounding factors. Being a replication study with association evidence supported by GWAS, 
multiple testing corrections were not applied. We regarded p-value of 0.05 was an acceptable 
cut-off for statistical significance. 
 
3. Results 
A total of 812 subjects participated in the study (462 LOAD and 350 non-demented controls). 
Consistent with previous studies, there was a higher prevalence of APOE ε4 carriers (presence 
of one or two ε4 alleles versus absence of ε4 allele) in LOAD patients (38%) than 
non-demented controls (16.6%) (p=2.27×10
-11
, OR=3.09) (Supplement table). 
 
All analyzed polymorphisms were satisfied with the Hardy-Weinberg equilibrium distribution 
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(p﹥0.001). For allele frequency association of CR1, both A allele of rs6656401 (p=0.034, 
OR=1.69) and T allele of rs3818361 (p=0.029, OR=1.27) were found to increase LOAD risk 
(Table 1). Further genotypic analysis of those two SNPs showed significant different 
distributions between LOAD and non-demented controls by applying a dominant model 
(Table 2). Neither allele frequency nor genotypic distribution was detected to be significant 
for PICALM by simple association analysis in our whole dataset. 
 
Since age and APOE ε4 status were of significant difference between groups, multivariate 
logistic regression analysis was employed (Table 3). After adjustment for age, sex and APOE 
ε4 status, the rs6656401 but not rs3818361 in CR1 remained of significant different 
distribution between disease and control groups. In contrast, both allele frequencies and 
genotypic distributions of rs2279590 and rs11136000 in CLU exhibited more significant 
protective effects after adjustment. Although, after multivariate logistic regression analysis no 
association was found for SNPs in PICALM between cases and controls among the entire 
dataset, significant LOAD association for rs3851179 of PICALM was found in the APOE ε4 
(-) but not in the APOE ε4 (+) subgroup. In the APOE ε4 (-) subgroup, compared to G allele, 
the A allele carrier of this SNP would decrease disease risk by 28% (adjusted p=0.028). The 
(AA+AG) genotype of this SNP carrier would reduce LOAD risk by 42% (adjusted p=0.013) 
compared to (GG) genotype (data not shown). 
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4. Discussion 
In our Hong Kong dataset, allelic association of the CR1 and CLU exhibited significant 
difference between LOAD cases and non-demented controls which were in agreement with 
previous studies (Harold, et al., 2009,Lambert, et al., 2009). By multivariate logistic 
regression analysis, the A allele of rs6656401 (adjusted OR=1.97) was identified as an 
independent genetic risk factor for LOAD, while the A allele of rs2279590 (adjusted OR=0.72) 
and T allele of rs11136000 (adjusted OR=0.73) were observed to be independent genetic 
protective factors for disease development. However, the adjusted OR of CR1 rs6656401 we 
presented here was of notable variance from Lambert’s original GWAS data (OR=1.21) 
(Lambert, et al., 2009). For CLU, adjusted ORs from our findings were similar to those in 
initial GWAS (0.86 ORs for both rs2279590 and rs11136000) (Harold, et al., 2009,Lambert, 
et al., 2009). Up to date, in addition to two published GWAS, another two case-controlled 
studies (Carrasquillo, et al., 2010,Corneveaux, et al., 2010) and one meta-analysis (Jun, et al., 
2010) carried out in parallel on Caucasians successfully demonstrated significant disease 
associations for CR1, CLU and PICALM with compatible genetic effect sizes (1.28 OR for 
CR1 rs6656401; 0.82-0.92 OR for CLU rs11136000). A replication study performed by 
Kamboh et al (Kamboh, et al., 2010) based on 2707 Caucasian Americans failed to detect 
significant LOAD associations for CR1, CLU and PICALM, however, further meta-analysis 
combing their own data with Lambert’s and/or Harold’s GWAS data demonstrated improved 
significant associations between these three genes and disease risk (1.18 OR for CR1 
rs6656401; 0.87, 0.86 ORs for CLU rs2279590 and rs11136000, separately). In contrast to the 
Caucasian population studies, the study of Zhang et al (Zhang, et al., 2010) which was 
9 
performed on Chinese ethnics in Shandong province (the northern part of China), showed 
significant association of CR1 and LOAD risk with 2.6 unadjusted OR for rs6656401. The 
disease allelic effect size was almost double compared to that of the Caucasian population and 
even 30% larger than that of our sample. Their result exhibited larger genetic effect tendency 
for polymorphism in CR1 which was similar with the findings from our southern Chinese 
population comparison to Caucasian population. On the contrary to obtaining usually 
decreased OR by replication study following the original GWAS, in Chinese, both the 
northern and southern populations investigated by independent research centers exhibited a 
larger genetic effect of polymorphism in CR1 compared to the Caucasian population. Thus, 
we hypothesize that CR1 confers LOAD susceptibility with more remarkable genetic effect in 
Chinese than in Caucasians. Nevertheless, it is necessary to clarify this association 
speculation in the future based on a much larger sample size.  
 
Although significant association was successfully replicated in CR1 and CLU based on our 
dataset, no genotyping difference in PICALM was identified between cases and controls 
among the entire dataset. However, after stratification our dataset according to the APOE ε4 
status, significant association for PICALM rs3851179 was found in the APOE ε4 (-) but not in 
the APOE ε4 (+) subgroup. The possible interpretation is due to the powerful APOE ε4 risky 
allele, which weakens the protective effect of polymorphism in the APOE ε4 (+) subgroup. 
Therefore, its disease association was exhibited only in the APOE ε4 (-) subgroup. Currently, 
it is notable that apolipoprotein E modulates amyloid-β (Aβ) peptide aggregation and 
clearance (Bell, et al., 2007,Holtzman, et al., 2000). Results from our study suggest that, by 
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interaction with APOE, PICALM may indirectly participate in amyloid precursor protein 
(APP) processing pathway and finally be involved in LOAD pathogenesis.  
 
Compared to the cited GWAS with thousands of subjects, our study was conducted on a much 
smaller sample size. This may partially explain why no association was observed for PICALM 
with LOAD in our whole dataset. However, we did show the evidences of CR1, CLU and 
PICALM and LOAD susceptibility based on our southern Chinese population. This successful 
follow-on study performed in an independent Chinese population provides additional 
evidence for LOAD association apart from prior GWAS in the Caucasian population. 
Biologically, complement receptor 1 encoded by CR1 has been revealed to be involved in 
clearance peripheral Aβ peptides (Rogers, et al., 2006). Clusterin encoded by CLU has been 
found to bind with Aβ to modulate Aβ metabolism (Bell, et al., 2007,DeMattos, et al., 2002) 
and related with oxidative stress as well as neuronal apoptosis (Nuutinen, et al., 
2009,Trougakos and Gonos, 2006). Phosphatidylinositol-binding clathrin assembly protein 
encoded by PICALM has been reported to participate in APP processing (Carey, et al., 
2005,Nordstedt, et al., 1993). Moreover, two new GWAS studies also indicated CR1, CLU 
and PICALM are associated with LOAD (Naj, et al., 2011, Hollingworth, et al., 2011). 
Combing above biological information with evidences from GWAS as well as our study, it is 
warranted to further investigate those genes’ function and to clarify their different roles in 
Alzheimer’s disease. 
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Table 1 Allelic association analysis of polymorphisms in CR1, CLU and PICALM 
with LOAD  
    
   Allele  
              All participants (AD=462, Control=350) 
AD (n, %) Control (n, %)      P OR(95%CI) 
CR1 
 
 
 
CLU 
 
 
 
 
 
PICALM 
 
 
rs6656401 
 
rs3818361 
 
rs9331888 
 
rs2279590 
 
rs11136000 
 
rs541458 
 
rs3851179 
A 
G 
T 
C 
C 
G 
A 
G 
T 
C 
C 
T 
A 
G 
53(5.79%) 
863(94.21%) 
316(34.73%) 
594(65.27%) 
453(49.45%) 
463(50.55%) 
189(21.05%) 
709(78.95%) 
192(21.29%) 
710(78.71%) 
439(48.89%) 
459(51.11%) 
364(39.82%) 
550(60.18%) 
24(3.49%) 
662(96.51%) 
201(29.56%) 
479(70.44%) 
335(48.98%) 
349(51.02%) 
159(23.38%) 
521(76.62%) 
162(23.96%) 
514(76.04%) 
338(49.71%) 
342(50.29%) 
275(40.32%) 
407(59.68%) 
0.034* 
 
0.029* 
 
0.850 
 
0.268 
 
0.207 
 
0.747 
 
0.840 
 
1.69(1.04-2.77) 
 
1.27(1.02-1.57) 
 
1.02(0.84-1.24) 
 
0.87(0.69-1.11) 
 
0.86(0.68-1.09) 
 
0.97(0.79-1.18) 
 
0.98(0.80-1.20) 
*P＜0.05 
Table 2 Genotypic association analysis of polymorphisms in CR1, CLU and 
PICALM with LOAD 
    
   Genotype  
              All participants (AD=462, Control=350) 
AD (n, %) Control (n, %)      P OR(95%CI) 
CR1 
 
 
 
 
 
CLU 
 
 
 
 
 
 
 
 
PICALM 
 
 
 
 
rs6656401a 
 
 
rs3818361a 
 
 
rs9331888b 
 
 
rs2279590b 
 
 
rs1113600b 
 
 
rs541458a 
 
 
rs3851179a 
AA 
AG 
GG 
TT 
TC 
CC 
CC 
CG 
GG 
AA 
AG 
GG 
TT 
TC 
CC 
CC 
CT 
TT 
AA 
AG 
GG 
2(0.4%) 
49(10.7%) 
407(88.9%) 
51(11.2%) 
214(47.0%) 
190(41.8%) 
109(23.8%) 
235(51.3%) 
114(24.9%) 
13(2.9%) 
163(36.3%) 
273(60.8%) 
15(3.3%) 
162(35.9%) 
274(60.8%) 
112(24.9%) 
215(47.9%) 
122(27.2%) 
77(16.8%) 
210(46.0%) 
170(37.2%) 
0(0%) 
24(7%) 
319(93%) 
27(8.0%) 
147(43.2%) 
166(48.8%) 
79(23.1%) 
177(51.8%) 
86(25.1%) 
21(6.2%) 
117(34.4%) 
202(59.4%) 
24(7.1%) 
114(33.7%) 
200(59.2%) 
92(27.1%) 
154(45.3%) 
94(27.6%) 
56(16.4%) 
163(47.8%) 
122(35.8%) 
0.048* 
 
 
0.047* 
 
 
0.817 
 
 
0.028* 
 
 
0.018* 
 
 
0.882 
 
 
0.679 
 
 
1.67(1.00-2.77) 
 
 
1.33(1.00-1.77) 
 
 
1.04(0.75-1.45) 
 
 
0.45(0.22-0.92) 
  
 
0.45(0.23-0.87) 
 
 
1.02(0.75-1.41) 
 
 
0.94(0.70-1.26) 
 
 
a Dominant model for genotypic analysis; b Recessive model for genotypic analysis 
*P＜0.05 
 
 
 
 
 
Table 3 Multivariate logistic regression analysis for polymorphisms in CR1, CLU 
and PICALM  
    Allele/Genotype P            OR(95%CI) 
CR1 
 
 
 
CLU 
 
 
 
 
 
PICALM 
 
 
rs6656401 
 
rs3818361 
 
rs9331888 
 
rs2279590 
 
rs11136000 
 
rs541458 
 
rs3851179 
A vs G 
AA+AG vs GG 
T vs C 
TT+TC vs CC 
C vs G 
CC vs CG+GG 
A vs G 
AA vs AG+GG 
T vs C 
TT vs TC+CC 
C vs T 
CC+CT vs TT 
A vs G 
AA+AG vs GG 
0.035*        1.97(1.05-3.71) 
0.043*        1.95(1.02-3.74) 
0.092         1.27(0.96-1.66) 
0.096         1.35(0.95-1.93) 
0.353         1.13(0.87-1.46) 
0.427         1.18(0.78-1.79) 
0.035*        0.72(0.53-0.98) 
0.006**       0.29(0.12-0.70) 
0.038*        0.73(0.54-0.98) 
0.009**       0.33(0.14-0.77) 
0.534         0.93(0.72-1.18) 
0.670         0.92(0.61-1.37) 
0.320         0.88(0.68-1.13) 
0.150         0.76(0.53-1.10) 
Adjustment P value with age, sex and APOEε4 status as covariates 
* P＜0.05, ** P＜0.01 
 
 
 
 
 
 
Supplement table Baseline characteristics of 812 Chinese participants 
 
   AD (n=462) Control (n=350) P 
Females (n, %) 
Male (n, %) 
Age, years (mean ± SD) 
ApoEε4 (+) carrier (n, %)  
ε3/ε4:ε3/ε3  
ε4/ε4:ε3/ε3 
330 (71.4%) 
132 (28.6%) 
79.4 ± 7.24 
175 (38%) 
149 (32.3%) 
17 (3.7%) 
248 (70.9%) 
102 (29.1%) 
70.7 ± 6.33 
58 (16.6%) 
48 (13.7%) 
3 (0.9%) 
0.86 
 
﹤0.001 
2.27×10-11 
1.24×10-9 
0.002 
 
